NYSEMKT: CANF
Can Fite Biopharma Ltd Stock Ownership - Who owns Can Fite Biopharma?

Insider buying vs selling

Have Can Fite Biopharma Ltd insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when CANF insiders and whales buy or sell their stock.

CANF Shareholders

What type of owners hold Can Fite Biopharma Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Rhumbline Advisers0.00%38,268$40.18kInstitution
Morgan Stanley0.00%23,212$24.37kInstitution
Bnp Paribas Financial Markets0.00%22,585$23.71kInstitution
Xtx Topco Ltd0.00%15,271$16.03kInstitution
Virtu Financial LLC0.00%13,740$14.43kInstitution
Captrust Financial Advisors0.00%10,634$11.17kInstitution
Fifth Third Bancorp0.00%3,000$3.15kInstitution
Wells Fargo Company0.00%2,700$2.84kInstitution
Costello Asset Management Inc0.00%1,000$1.05kInstitution
National Bank Of Canada0.00%600$630.00Institution

1 of 2

CANF vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CANF0.00%0.00%
ACXP14.90%10.95%Net Buying
LIPO0.06%39.77%
IMRN0.00%0.00%
CYCN11.60%88.40%Net SellingNet Buying

Can Fite Biopharma Stock Ownership FAQ

Who owns Can Fite Biopharma?

Can Fite Biopharma (NYSEMKT: CANF) is owned by 0.00% institutional shareholders, 0.00% Can Fite Biopharma insiders, and 100.00% retail investors. Rhumbline Advisers is the largest individual Can Fite Biopharma shareholder, owning 38,268.00 shares representing 0.00% of the company. Rhumbline Advisers's Can Fite Biopharma shares are currently valued at $40.18k.

If you're new to stock investing, here's how to buy Can Fite Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.